Tessera Therapeutics
Cambridge
About Tessera Therapeutics
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 251 – 500
- Total funding: $773.1M
- Last round: Grant (Mar 2026)
- Website: tesseratherapeutics.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Genetics, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/tessera-therapeutics-22685 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.